Aydah AlAwadhi, Consultant Medical Oncologist and Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, Abu Dhabi, shared a post on LinkedIn:
“The future of triple-negative breast cancer treatment is pivoting heavily toward bispecific antibodies and bispecific antibody-drug conjugates!
One of the most impressive TNBC datasets presented at the American Society of Clinical Oncology (ASCO) 2026 that deserves more attention!
The phase III PANKU-Breast02 trial randomized 406 patients with previously treated unresectable locally advanced/metastatic TNBC to izalontamab brengitecan (iza-bren) EGFRxHER3 Bispecific ADC (n=207) or physician’s choice chemotherapy (n=205).
PFS: 8.5 vs 3.1 months
HR 0.29 (95% CI, 0.22–0.38; P<0.0001)
71% reduction in the risk of progression or death
PFS rates
- 6 months: 62.0% vs 17.6%
- 9 months: 47.7% vs 7.7%
OS: 15.9 vs 12.5 months
HR 0.60 (95% CI, 0.42–0.85; P=0.0019)
40% reduction in the risk of death
OS rates
- 9 months: 79.9% vs 68.7%
- 12 months: 67.5% vs 53.5%
Bottom line: Iza-bren significantly improved both PFS and OS, delivering a clinically meaningful 5.4-month PFS gain and 3.4-month OS gain in previously treated metastatic TNBC.”
Can Breast-Conserving Surgery Be Oncologically Safe for Multiple Ipsilateral Breast Cancers?
